{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T21:15:17Z","timestamp":1778447717387,"version":"3.51.4"},"reference-count":23,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2016-0102_s_999_w2aab3b7b1b1b6b1aab1c17b1Aa\">\n                    <jats:title id=\"d1987534e415_w2aab3b7b1b1b6b1aab1c17b1aAa\">Background:<\/jats:title>\n                    <jats:p>Anemia aggravates the disease course and the survival rate of chronic heart failure (CHF) patients. The purpose of the study was to investigate the level of erythropoietin (EPO) in CHF patients with anemic syndrome, with the aim to more accurately assess the severity of the disease and its treatment, depending on the anemia degree.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2016-0102_s_998_w2aab3b7b1b1b6b1aab1c17b2Aa\">\n                    <jats:title id=\"d1987534e423_w2aab3b7b1b1b6b1aab1c17b2aAa\">Methods:<\/jats:title>\n                    <jats:p>Patients with ischemic CHF of I\u2013IV functional class (FC) with and without anemia were examined (total number of patients=208, patients with anemia=174). The EPO was determined using the enzyme-linked immunosorbent assay. Before treatment, the patients underwent the following medical therapy: angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, long-acting nitrates, diuretics, digoxin, and beta-blockers at individual doses. Depending on the plasma EPO level, the CHF patients with anemia were divided into four randomized groups in terms of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2016-0102_s_997_w2aab3b7b1b1b6b1aab1c17b3Aa\">\n                    <jats:title id=\"d1987534e431_w2aab3b7b1b1b6b1aab1c17b3aAa\">Results:<\/jats:title>\n                    <jats:p>Normal erythropoietinemia was found in 36.2% of the CHF patients with anemic syndrome (I\u2013III FC), hypoerythropoietinemia in 44.8% (III\u2013IV FC), and hypererythropoietinemia in 18.96% (III\u2013V FC). The EPO level in the blood plasma of the patients with I\u2013II FC CHF with hypoerythropoietinemia, who were treated with methoxy polyethylene glycol-epoetin \u03b2 (MEB), increased by 2.2 times. Combination therapy with disease-modifying drugs and MEB led to a significant increase in the plasma EPO level in the CHF patients with hypoerythropoietinemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2016-0102_s_996_w2aab3b7b1b1b6b1aab1c17b4Aa\">\n                    <jats:title id=\"d1987534e439_w2aab3b7b1b1b6b1aab1c17b4aAa\">Conclusions:<\/jats:title>\n                    <jats:p>It was shown that the EPO level in patients with CHF and anemia did not always drop. Hypererythropoietinemia in patients with CHF and anemia leads to an unfavorable treatment prediction. This necessitates the investigation of the EPO level in all patients with CHF before and after treatment, with the aim of correcting the anemic syndrome. The research showed that the combined therapy of patients with CHF and anemia using MEB medication and iron with regard to the EPO level in the blood plasma improved their overall physical condition, reduced heart failure symptoms and hospitalization frequency, and demonstrated a clear tendency to reduce the general mortality rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2016-0102","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T17:16:22Z","timestamp":1512666982000},"page":"11-17","source":"Crossref","is-referenced-by-count":6,"title":["Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia"],"prefix":"10.1515","volume":"29","author":[{"given":"Kamala Kh.","family":"Zahidova","sequence":"first","affiliation":[{"name":"Department of Cardiology of Azerbaijan State Advanced Training Institute for Doctors named after A. Aliyev , Baku , The Republic of Azerbaijan , Phone: (994) 12 4314033"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,12,7]]},"reference":[{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_001_w2aab3b7b1b1b6b1ab1b7b1Aa","doi-asserted-by":"crossref","unstructured":"Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the anemia in chronic heart failure: outcomes and resource utilization (ANCHOR) study. Circulation 2006;113:2713\u201323.10.1161\/CIRCULATIONAHA.105.57757716754803","DOI":"10.1161\/CIRCULATIONAHA.105.577577"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_002_w2aab3b7b1b1b6b1ab1b7b2Aa","doi-asserted-by":"crossref","unstructured":"Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818\u201327.10.1016\/j.jacc.2008.04.06118755344","DOI":"10.1016\/j.jacc.2008.04.061"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_003_w2aab3b7b1b1b6b1ab1b7b3Aa","doi-asserted-by":"crossref","unstructured":"Anand IS. Anemia and chronic heart failure. Implications and treatment options. J Am Coll Cardiol 2008;52:501\u201311.10.1016\/j.jacc.2008.04.04418687241","DOI":"10.1016\/j.jacc.2008.04.044"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_004_w2aab3b7b1b1b6b1ab1b7b4Aa","doi-asserted-by":"crossref","unstructured":"Tang Y-D, Katz SD. Anemia in chronic heart failure. Prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454\u201361.1671716410.1161\/CIRCULATIONAHA.105.583666","DOI":"10.1161\/CIRCULATIONAHA.105.583666"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_005_w2aab3b7b1b1b6b1ab1b7b5Aa","doi-asserted-by":"crossref","unstructured":"van der Meer P, Lok DJ, Januzzi JL, Lipsic E, van Wijngaarden J, Voors AA, et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. Europ Heart J 2008;29:1510\u20135.10.1093\/eurheartj\/ehn205","DOI":"10.1093\/eurheartj\/ehn205"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_006_w2aab3b7b1b1b6b1ab1b7b6Aa","doi-asserted-by":"crossref","unstructured":"Stamosa TD, Silver MA. Management of anemia in heart failure. Curr Opin Cardiol 2010;25:148\u201354.10.1097\/HCO.0b013e3283357fe019996965","DOI":"10.1097\/HCO.0b013e3283357fe0"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_007_w2aab3b7b1b1b6b1ab1b7b7Aa","doi-asserted-by":"crossref","unstructured":"Moe GW, Ezekowitz JA, O\u2019Meara E, Lepage S, Howlett JG, Fremes S, et al. The 2014 Canadian cardiovascular society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol 2015;31:3\u201316.10.1016\/j.cjca.2014.10.022","DOI":"10.1016\/j.cjca.2014.10.022"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_008_w2aab3b7b1b1b6b1ab1b7b8Aa","doi-asserted-by":"crossref","unstructured":"Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003;107:223\u20135.1253841810.1161\/01.CIR.0000052622.51963.FC","DOI":"10.1161\/01.CIR.0000052622.51963.FC"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_009_w2aab3b7b1b1b6b1ab1b7b9Aa","doi-asserted-by":"crossref","unstructured":"Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002;40:1414\u201321.10.1016\/S0735-1097(02)02304-512392830","DOI":"10.1016\/S0735-1097(02)02304-5"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_010_w2aab3b7b1b1b6b1ab1b7c10Aa","doi-asserted-by":"crossref","unstructured":"Gao E, Koch WJ. Is erythropoietin behind maladaptive anemic heart failure? Am J Physiol Heart Circ Physiol 2009;296:H559\u201360.10.1152\/ajpheart.00045.200919168730","DOI":"10.1152\/ajpheart.00045.2009"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_011_w2aab3b7b1b1b6b1ab1b7c11Aa","unstructured":"Kallergis EM, Mavrakis HE, Vardas PE. Anaemia and heart failure: is its correction a therapeutic target? The role of erythropoietin. Hell J Cardiol 2005;46:222\u20135."},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_012_w2aab3b7b1b1b6b1ab1b7c12Aa","doi-asserted-by":"crossref","unstructured":"Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59:538\u201348.1449985510.1016\/S0008-6363(03)00468-1","DOI":"10.1016\/S0008-6363(03)00468-1"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_013_w2aab3b7b1b1b6b1ab1b7c13Aa","doi-asserted-by":"crossref","unstructured":"van der Meera P, Voorsa AA, Lipsica E, van Gilstb WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Europ Heart J 2004;25:285\u201391.10.1016\/j.ehj.2003.11.017","DOI":"10.1016\/j.ehj.2003.11.017"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_014_w2aab3b7b1b1b6b1ab1b7c14Aa","doi-asserted-by":"crossref","unstructured":"Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabr\u00f2 A. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006;152:1096\u2013115.17161060","DOI":"10.1016\/j.ahj.2006.08.005"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_015_w2aab3b7b1b1b6b1ab1b7c15Aa","doi-asserted-by":"crossref","unstructured":"George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T, et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure. Comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005;165:1304\u201309.1595601210.1001\/archinte.165.11.1304","DOI":"10.1001\/archinte.165.11.1304"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_016_w2aab3b7b1b1b6b1ab1b7c16Aa","doi-asserted-by":"crossref","unstructured":"Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226\u20139.10.1161\/01.CIR.0000052623.16194.8012538419","DOI":"10.1161\/01.CIR.0000052623.16194.80"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_017_w2aab3b7b1b1b6b1ab1b7c17Aa","doi-asserted-by":"crossref","unstructured":"Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737\u201344.10.1016\/S0735-1097(00)00613-6","DOI":"10.1016\/S0735-1097(00)00613-6"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_018_w2aab3b7b1b1b6b1ab1b7c18Aa","doi-asserted-by":"crossref","unstructured":"Pham I, Andrivet P, Sediame S, Defouilloy C, Moutereau S, Wirquin V, et al. Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics. Eur J Clin Invest 2001;31:103\u20139.1116844610.1046\/j.1365-2362.2001.00774.x","DOI":"10.1046\/j.1365-2362.2001.00774.x"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_019_w2aab3b7b1b1b6b1ab1b7c19Aa","doi-asserted-by":"crossref","unstructured":"Silverberg D, Waxler D, Blum M, Wollman Y. The interaction between heart failure, renal failure and anemia \u2013 the cardio-renal anemia syndrome. Blood Purify 2004;22:277\u201384.10.1159\/000078698","DOI":"10.1159\/000078698"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_020_w2aab3b7b1b1b6b1ab1b7c20Aa","unstructured":"Zahidova KK. The role of the level of serum erythropoietin on the patients with anemic heart failure. Eur J Heart Fail (Supplements) 2013;12(S1):71."},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_021_w2aab3b7b1b1b6b1ab1b7c21Aa","doi-asserted-by":"crossref","unstructured":"Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 2002;4:681\u20136.10.1016\/S1388-9842(02)00115-012453537","DOI":"10.1016\/S1388-9842(02)00115-0"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_022_w2aab3b7b1b1b6b1ab1b7c22Aa","doi-asserted-by":"crossref","unstructured":"Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775\u201380.10.1016\/S0735-1097(01)01248-7","DOI":"10.1016\/S0735-1097(01)01248-7"},{"key":"2025121209223338631_j_jbcpp-2016-0102_ref_023_w2aab3b7b1b1b6b1ab1b7c23Aa","doi-asserted-by":"crossref","unstructured":"van Veldhuisen DJ, McMurray JJ. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 2007;9:110\u20132.1727049310.1016\/j.ejheart.2007.01.004","DOI":"10.1016\/j.ejheart.2007.01.004"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jbcpp.2018.29.issue-1\/jbcpp-2016-0102\/jbcpp-2016-0102.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2016-0102\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2016-0102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:21:26Z","timestamp":1765542086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2016-0102\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,7]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12,7]]},"published-print":{"date-parts":[[2018,1,26]]}},"alternative-id":["10.1515\/jbcpp-2016-0102"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2016-0102","relation":{},"ISSN":["2191-0286","0792-6855"],"issn-type":[{"value":"2191-0286","type":"electronic"},{"value":"0792-6855","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,7]]}}}